Thyroid Unit, Division of Endocrinology, Metabolism, and Diabetes, The Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
Endocr Pract. 2012 Sep-Oct;18(5):796-802. doi: 10.4158/EP12183.RA.
To describe the molecular markers thus far evaluated for use in the care of patients with clinically relevant thyroid nodules.
We review the currently available molecular tests that have been applied to patients with thyroid nodules.
In the United States, approximately 450 000 diagnostic fine-needle aspirates will be performed on patients with thyroid nodules this year in an effort to identify thyroid cancer. Unfortunately, this test is imprecise and, at times, inaccurate. Because of this, novel diagnostic testing modalities have been pursued, the most promising of which involve molecular analysis of thyroid tissue. Immunohistochemical staining, analysis for mutations and gene rearrangements, and microarray analysis have all been investigated with regard to their performance characteristics in targeted patient populations.
Molecular tests to evaluate thyroid nodules demonstrate variable performance characteristics. Further evaluation of available and emerging molecular tests will necessarily rely on prospective real-world test validation in the clinical setting.
描述迄今为止用于临床相关甲状腺结节患者护理的分子标志物。
我们回顾了目前已应用于甲状腺结节患者的分子检测方法。
今年,美国将有大约 45 万例甲状腺结节患者接受细针抽吸诊断检查,以确定是否患有甲状腺癌。不幸的是,这种检测并不精确,有时也不准确。正因为如此,人们一直在寻求新的诊断检测方法,其中最有前途的方法是对甲状腺组织进行分子分析。针对特定患者人群,免疫组织化学染色、基因突变和基因重排分析以及微阵列分析均已被用于评估其性能特征。
用于评估甲状腺结节的分子检测方法显示出不同的性能特征。进一步评估现有和新兴的分子检测方法,必然需要在临床环境中进行前瞻性真实世界检测验证。